We are live on ! Find out more
JNP

Juniper Pharmaceuticals, Inc. Common Stock
JNP

Delisted

JNP was delisted on the 13th of August, 2018.

31 hedge funds and large institutions have $11M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

380% more call options, than puts

Call options by funds: $264K | Put options by funds: $55K

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

9% more capital invested

Capital invested by funds: $10.1M → $11M (+$939K)

3% more funds holding

Funds holding: 3031 (+1)

Holders
31
Holders Change
+1
Holders Change %
+3.33%
% of All Funds
0.9%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
10
Reduced
6
Closed
5
Calls
$264K
Puts
$55K
Net Calls
+$209K
Net Calls Change
-$195K

JNP Hedge Fund Activity: Q4 2013 in Review

31 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q4 2013, worth a combined $11M — up 9.3% from $10.1M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new JNP positions and 5 closed out — a net gain of 1 holder — while 10 added to existing stakes and 6 trimmed.

The largest buyer was David M. Knott, opening a new position worth an estimated $1.09M. The largest seller was Numeric Investors, exiting entirely with an estimated $577K sold.

  • 31 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q4 2013, up from 30 in Q3 2013.
  • Funds reported $11M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q4 2013, up 9.3% quarter-over-quarter.
  • 6 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q4 2013 and 5 closed out, a net change of +1 holder.
  • The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q4 2013 was David M. Knott, an estimated $1.09M added.
  • The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q4 2013 was Numeric Investors, an estimated $577K sold.

Based on aggregated 13F filings for Q4 2013.